The catch: legal and regulatory certainty is reduced. Retatrutide was in no way about the FDA drug scarcity checklist (since it was in no way permitted), so compounders featuring it work underneath additional tenuous authorized framing than people who dealt with semaglutide or tirzepatide through the 2023–2024 shortages. Pricing could shift as en